1. Generic Imatinib Therapy Among Jordanians: An Observational Assessment of Efficacy and Safety in Routine Clinical Practice 
Abdalla Awidi, Salah Abbasi, Kamal Alrabi, Khalid A. Kheirallah 
Clinical Lymphoma, Myeloma and Leukemia 
Volume 17, Issue 12, Pages e55-e61 (December 2017)
DOI: /j.clml
Copyright © 2017 The Authors Terms and Conditions

2. Figure 1 Flowchart of Patients
Clinical Lymphoma, Myeloma and Leukemia  , e55-e61DOI: ( /j.clml )
Copyright © 2017 The Authors Terms and Conditions

3. Figure 2
Response in the First-line Patients at Month 12. Ten (30% of 33) Patients Had No Efficacy Data at Month 12, and Therefore Were Excluded From the Evaluable Patients and Included in the ITT Population
Abbreviations: CCyR = complete cytogenetic response; ITT = intention-to-treat; MMR = major molecular response; PCyR = partial cytogenic response.
Clinical Lymphoma, Myeloma and Leukemia  , e55-e61DOI: ( /j.clml )
Copyright © 2017 The Authors Terms and Conditions

4. Figure 3
Response in Switched Patients at Month 12. Three (5% of 58) Patients Had No Efficacy Data at Month 12, and Therefore Were Excluded From the Evaluable Patients and Included in the ITT Population
Abbreviations: CCyR = complete cytogenetic response; ITT = intention-to-treat; MMR = major molecular response; PCyR = partial cytogenic response.
Clinical Lymphoma, Myeloma and Leukemia  , e55-e61DOI: ( /j.clml )
Copyright © 2017 The Authors Terms and Conditions